Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Health Universe Raises $6M to Integrate AI Agents into Healthcare Organizations
Secure, HIPAA-Compliant Platform Reduces Months of Manual Work to Days for Leading Research Institutions and Health Systems
Health Universe, the enterprise AI platform that automates complex healthcare workflows, today announced $6 million in seed funding led by Kleiner Perkins, bringing its total funding to $9.5 million to date. The round follows a 2023 pre-seed backed by Susa Ventures, Twelve Below, and Oncology Ventures. The new capital will accelerate adoption across leading academic medical centers (AMCs), health systems, and life sciences organizations as Health Universe establishes itself as the definitive AI infrastructure layer for healthcare, oncology, and clinical research.
Healthcare organizations are under mounting pressure as clinician burnout rises, staff are overwhelmed by administrative burdens, and clinical trial timelines routinely stretch nearly eight months before a single patient is enrolled. While AI tools have demonstrated promise across healthcare, most systems remain black boxes, making them difficult to audit and to safely deploy in high-stakes clinical environments. Health Universe addresses this gap by providing a secure, compliant workspace to deploy inspectable, auditable agents designed for regulated healthcare settings. In less than a year since launching Navigator, the platform has processed over 170M clinical documents.
Health Universe serves as an AI workflow engine for healthcare organizations, enabling them to build, deploy, and govern autonomous and human-in-the-loop agents within a secure, ONC-certified, HIPAA-compliant environment. Its platform includes:
- Navigator: A secure organizational workspace for deploying, managing, and monitoring agents that run over a patient record; users can retrieve patient records from TEFCA, FHIR, or direct upload and run off-the-shelf agents, custom agents, or vendor contributed agents
- Explorer: A population-level workspace to build cohorts and execute agents
- Observer: Monitors agents for cost, hallucination, and high-risk scenario flagging
- Oncology Agents: Transforms fragmented medical records into structured, source-linked oncology summaries, including diagnosis, staging, biomarkers, treatment history, and disease progression, reducing hours of chart review to minutes; deployed at several leading oncology practices and New York Cancer and Blood Specialists
- Clinical Trials Agents: A multi-agent system that converts brief study synopses into comprehensive 75-page clinical trial protocols, with automated ClinicalTrials.gov submissions and Institutional Review Board workflow integration. Built in conjunction with Duke Clinical Research Institute
“Healthcare doesn’t need another chatbot,” said Dan Caron, Founder and CEO at Health Universe…
Full release here, originally announced March 19th, 2026.
Verily Secures $300 Million Investment to Advance its Precision Health AI Strategy
Funding Round Led by Series X Capital, with Additional Backing from Alphabet, UCHealth, and the University of Colorado Anschutz
Verily today announced a $300 million investment round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors, to advance the next phase of its precision health AI strategy. With this funding round, Alphabet will be a significant minority investor in Verily, while no longer having a controlling stake.
“Today is an important step in our mission to bring the promise of precision health to everyone,” said Stephen Gillett, Chairman and CEO at Verily. “From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare – one that is as precise as it is personal. Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz, and our many investors will be fantastic partners in this transformation of healthcare.”
With this investment, Verily has transitioned its legal structure from an LLC to a corporation, with the official new name of Verily Health Inc, and plans to accelerate its AI-native precision health platform strategy and roadmap to help customers harmonize their healthcare data, model, and deploy actionable intelligence into research and care workflows.
Verily has recently announced a number of commercial partnerships, including a new collaboration with Samsung’s Galaxy Watch to help life sciences customers accelerate clinical research through biomarker development on the Pre platform, and a strategic partnership with Salesforce, announcing integration of the Verily Pre Platform with Agentforce Health to power enterprise precision health solutions. These announcements build on Verily’s recent strategic collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience, who are using the Verily Pre platform for AI-powered research and care transformation.
“Series X Capital was established in collaboration with Google’s X, The Moonshot Factory to scale moonshot technologies into consequential, world-changing companies. We are extremely excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health,” said Gideon Yu, Founder and Managing Partner at Series X Capital.
Verily initially graduated from Google X ten years ago, as one of Alphabet’s earliest “Other Bets”, with a focus on breakthrough science and health tech innovation…
Full release here, originally announced March 19th, 2026.
No comments:
Post a Comment